GlassScriptPhysician profile
Heidi M Furth
NPI 1669530671
$6,088.72
in general payments reported to CMS, 2019-2025
20 companies · $1,040 in 2025
The $1,040 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,039 · 2022: $1,291 · 2023: $1,498 · 2024: $1,220 · 2025: $1,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,241 · Education: $518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,240.73 |
| Education | $517.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,291.49 | 2021-2025 | |
| Janssen Biotech, INC. | $969.71 | 2021-2025 | Tremfya |
| Genzyme Corporation | $661.44 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $636.99 | 2021-2024 | Ilumya, Odomzo, Blu-U |
| Regeneron Healthcare Solutions, INC. | $464.04 | 2021-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $406.74 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $347.10 | 2021-2025 | |
| Ucb, INC. | $320.37 | 2021-2025 | Bimzelx, Cimzia |
| Amgen INC. | $286.96 | 2021-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $166.16 | 2022-2025 | Sotyktu |
| Pfizer INC. | $146.28 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $89.95 | 2024 | |
| Arcutis Biotherapeutics, INC. | $85.07 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $68.91 | 2023-2025 | Adbry, Anzupgo, Spevigo |
| Organon LLC | $48.06 | 2024-2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $35.28 | 2021 | |
| Organogenesis INC. | $19.58 | 2024 | |
| Vyne Pharmaceuticals INC. | $16.27 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.23 | 2024 | Cyltezo |
| Dermavant Sciences, INC. | $14.09 | 2023 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Furth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.